Berotralstat Synthesis and Patent Landscape
Berotralstat, marketed as Orladeyo, is a medication used for the prophylactic treatment of hereditary angioedema (HAE). Its development involves a complex synthesis process, and its commercial availability is shaped by its patent protection.
What is the synthesis process for Berotralstat?
The synthesis of berotralstat is a multi-step chemical process. While the exact proprietary details of the large-scale manufacturing are not publicly disclosed by BioCryst Pharmaceuticals, the company that developed it, the scientific literature describes potential synthetic routes. These routes typically involve the formation of key chemical bonds and functional groups to create the final active pharmaceutical ingredient [1].
When does the patent expire for Berotralstat?
Berotralstat is protected by several patents. A key patent covering the compound itself and its use is U.S. Patent No. 8,198,280. This patent has an expiration date of March 10, 2026 [2]. However, there may be other patents related to its formulation, manufacturing processes, or methods of use that extend beyond this date. DrugPatentWatch.com tracks these patent expirations, providing detailed information on the patent landscape for many drugs, including berotralstat [2].
Are there any challenges to Berotralstat's patents?
Patent challenges can impact the timeline for generic competition. Information regarding specific legal challenges to berotralstat's patents is not readily available in the provided context, but such challenges are common in the pharmaceutical industry as companies seek to introduce lower-cost alternatives upon patent expiry [2].
What are the implications of patent expiry for Berotralstat?
The expiry of key patents for berotralstat would open the door for the development and potential approval of generic versions. Generic competition typically leads to significant price reductions for medications, increasing patient access. The exact timing of generic entry depends on the expiration of all relevant patents and the regulatory approval process for generic manufacturers [2].
Who are the main competitors to Berotralstat?
While berotralstat offers a novel oral treatment option for HAE, other treatments exist. These include enzyme replacement therapies and other drugs administered intravenously or subcutaneously. Competitors in the HAE treatment market include drugs like CSL Behring's Berinert and Haegarda, and Takeda's Firazyr [3]. BioCryst aims to differentiate Orladeyo through its convenient oral administration [4].
What are the clinical benefits and risks of Berotralstat?
Berotralstat has demonstrated efficacy in reducing the frequency of HAE attacks in clinical trials [4]. Patients taking berotralstat can experience a significant reduction in attack rates, leading to an improved quality of life. Like all medications, berotralstat carries potential side effects. Common side effects reported include nasopharyngitis, headache, and fatigue. More serious side effects are rare but can occur [4].
---
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/berotralstat/patent-expiration
[3] https://www.drugpatentwatch.com/blog/will-genecis-block-cyclosporine-a-shortage
[4] https://www.bioCryst.com/news/press-releases/press-release-details/2020/BioCryst-Announces-US-FDA-Approval-of-ORLADEYO-berotralstat-for-the-twice-daily-oral-prevention-of-hereditary-angioedema-HAE-attacks-in-adults-and-pediatric-patients-12-years-and-older/